NCT01787747View on ClinicalTrials.gov

Pharmacokinetics (PK) and Tolerability of AVP-786 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Healthy
Interventions
DRUG

AVP-786 Dose 1

DRUG

AVP-786 Dose 2

DRUG

AVP-786 Dose 1/Q Dose 1

DRUG

AVP-786 Dose 1/Q Dose 2

DRUG

AVP-786 Dose 2/Q Dose 2

DRUG

AVP-923

Trial Locations (1)

5000

CMAX, Adelaide

Sponsors
All Listed Sponsors
lead

Avanir Pharmaceuticals

INDUSTRY

NCT01787747 - Pharmacokinetics (PK) and Tolerability of AVP-786 in Healthy Volunteers | Biotech Hunter | Biotech Hunter